New images of the virus from researchers at the University of Wisconsin–Madison may hold the key to preventing or slowing RSV infections. advertisement Phys.org ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically attended lower respiratory infections and an 84.3% reduction in respiratory ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns, Merck announced.Merck said it plans to make the ...

Connecticut saw a drop in Respiratory Syncytial Virus, or RSV, cases during the 2025 season, according to statistics by the state Department of Public Health (DPH). RSV season ...

New images of RSV may expose stubborn virus's weak points Date: October 1, 2024 Source: University of Wisconsin-Madison Summary: The complex shape of respiratory syncytial virus is one hurdle ...

New images of the virus from researchers at the University of Wisconsin–Madison may hold the key to preventing or slowing RSV infections. RSV is of greatest concern in young children, the ...

The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...